Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for medical industry professionals · Sunday, December 16, 2018 · 471,302,473 Articles · 3+ Million Readers

$543 Million Triple Negative Breast Cancer (TNBC) Market Insight, Epidemiology and Market Forecast, 2027

/EIN News/ -- Dublin, Dec. 05, 2018 (GLOBE NEWSWIRE) -- The "Triple Negative Breast Cancer (TNBC) - Market Insight, Epidemiology and Market Forecast" drug pipelines has been added to's offering.

The Triple Negative Breast Cancer (TNBC) - Market Insight, Epidemiology and Market Forecast-2027' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of TNBC in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), Japan and China.

The report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Triple Negative Breast Cancer (TNBC) from 2016 to 2027 segmented by G8 markets. The report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Triple Negative Breast Cancer (TNBC) - Disease Understanding and Treatment Algorithm

The Triple Negative Breast Cancer (TNBC) market report gives the thorough understanding of the Triple Negative Breast Cancer by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Triple Negative Breast Cancer in the US, Europe, Japan and China.

Triple Negative Breast Cancer Epidemiology

The Triple Negative Breast Cancer (TNBC) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every G8 Countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.

This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total diagnosed incident cases and sub-type specific incident cases) scenario of Triple Negative Breast Cancer (TNBC) in the G8 Countries covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom), Japan and China from 2016-2027.

The total number of diagnosed incident population of Triple Negative Breast Cancer (TNBC) was found to be 123,914 in the year 2016.

Triple Negative Breast Cancer Drug Chapters

This segment of the Triple Negative Breast Cancer report encloses the detailed analysis of marketed drugs and late stage (Registration, Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details of each included drug and the latest news and press releases.

At present, systemic chemotherapy remains the mainstay for the treatment of TNBC due to lack of targeted therapies and contributes towards the market size of TNBC. The several therapeutic classes of the drugs include DNA repair complex like (platinum compounds and taxanes), p53 like (taxanes), cell proliferation like (anthracycline containing regimen) and targeted therapy. Detailed chapter for upcoming therapies like Sacituzumab Govitecan (Immunomedics), Atezolizumab (Roche), Pembrolizumab (Merck), Ipatasertib (Roche), Enzalutamide (Pfizer/Astellas), Cobimetinib (Roche), Rucaparib (Clovis Oncology), Niraparib (Tesaro) and Capitasertib (AstraZeneca) have been covered in the report.

Triple Negative Breast Cancer Market Outlook

The Triple Negative Breast Cancer market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

The market of Triple Negative Breast Cancer in G8 Countries was found to be USD 0.543 billion in 2016, and is expected to increase from 2016-2027.

Key Topics Covered:

1. Key Insights

2. Triple Negative Breast Cancer Market Overview at a Glance
2.1. Market Share (%) Distribution of Triple Negative Breast Cancer in 2016
2.2. Market Share (%) Distribution of Triple Negative Breast Cancer in 2027

3. Disease Background and Overview: Triple Negative Breast Cancer
3.1. Introduction
3.2. Types of Breast Cancer
3.3. Risk factors
3.4. Molecular Subtypes in Triple Negative Breast Cancer
3.5. Mutations Associated with Triple Negative Breast Cancer
3.6. Pathogenesis
3.7. Signs and Symptoms
3.8. Diagnosis
3.9. Diagnostic Guidelines
3.10. Stages of Triple Negative Breast Cancer
3.11. Molecular Markers for TNBC and Basal-like Breast Cancer

4. Unmet Needs

5. Epidemiology and Patient Population
5.1. Key Findings
5.2. Population and Forecast Parameters
5.3. Total Diagnosed Incident Cases of TNBC in G8 countries

6. Country Wise-Epidemiology of TNBC

7. Treatment Practices
7.1. Treatment
7.2. Treatment Guidelines

8. Marketed Drug Analysis
8.1. Lynparza: AstraZeneca

9. Emerging Therapies
9.1. Emerging Drugs Analysis
9.1.1. Sacituzumab Govitecan: Immunomedics
9.2. Atezolizumab: Roche
9.3. Pembrolizumab: Merck
9.4. Ipatasertib: Roche
9.5. Enzalutamide: Pfizer/Astellas
9.6. Cobimetinib: Hoffman La Roche
9.7. Rucaparib: Clovis Oncology
9.8. Niraparib: Tesaro
9.9. Capivasertib: AstraZeneca

10. Triple Negative Breast Cancer [TNBC]: G8 Countries Market Analysis
10.1. Key Findings
10.2. Total Market Size of Triple Negative Breast Cancer (TNBC) in G8 Countries
10.3. G8 Countries Market Size of TNBC by First Line of Therapies
10.4. G8 Countries Market Size of TNBC by Second Line of Therapies

11. Market Outlook by Country

12. Market Drivers

13. Market Barriers

14. Appendix

For more information about this drug pipelines report visit

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

                             Laura Wood, Senior Press Manager
                             For E.S.T Office Hours Call 1-917-300-0470
                             For U.S./CAN Toll Free Call 1-800-526-8630
                             For GMT Office Hours Call +353-1-416-8900
                    Related Topics: Breast Cancer Drugs 


Powered by EIN News

EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release